Scarica l'app Stockscreener
0.8195
2.57%
0.0205
Dopo l'orario di chiusura:
.82
0.0005
+0.06%
Precedente Chiudi:
$0.799
Aprire:
$0.7999
Volume 24 ore:
98,835
Relative Volume:
0.73
Capitalizzazione di mercato:
$16.03M
Reddito:
$411.00K
Utile/perdita netta:
$-4.85M
Rapporto P/E:
-1.8625
EPS:
-0.44
Flusso di cassa netto:
$-4.88M
1 W Prestazione:
-3.02%
1M Prestazione:
+0.61%
6M Prestazione:
-48.78%
1 anno Prestazione:
-73.98%
Intervallo 1D:
$0.78
$0.8493
Intervallo di 1 settimana:
$0.7777
$0.85
Portata 52W:
$0.7777
$4.38
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Nome
Lexaria Bioscience Corp
Settore
Industria
Telefono
250-765-6424
Indirizzo
100 - 740 MCCURDY ROAD, KELOWNA
Confronta LEXX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.8195 | 15.63M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexaria Bioscience Corp Borsa (LEXX) Ultime notizie
Will Lexaria Bioscience Corp. Equity Warrant bounce back from current supportWeekly Loss Report & High Return Stock Watch Alerts - Newser
Pattern recognition hints at Lexaria Bioscience Corp. upsideJuly 2025 Trends & Free Weekly Chart Analysis and Trade Guides - Newser
Will Lexaria Bioscience Corp. continue its uptrend2025 Market Overview & Precise Buy Zone Tips - Newser
Is it too late to sell Lexaria Bioscience Corp. Equity WarrantJuly 2025 Catalysts & Verified Momentum Stock Ideas - Newser
Lexaria Bioscience Completes Key Phase 1b Study Milestone - MSN
Risk adjusted return profile for Lexaria Bioscience Corp. analyzedJuly 2025 Weekly Recap & Real-Time Chart Pattern Alerts - Newser
What’s the recovery path for long term holders of Lexaria Bioscience Corp. Equity WarrantPortfolio Growth Summary & Daily Technical Stock Forecast Reports - Newser
What to expect from Lexaria Bioscience Corp. Equity Warrant in the next 30 daysRisk Management & Expert Approved Momentum Trade Ideas - Newser
Will earnings trigger a reversal in Lexaria Bioscience Corp. Equity WarrantTrade Volume Report & Smart Allocation Stock Reports - Newser
Chart based analysis of Lexaria Bioscience Corp. Equity Warrant trendsMarket Risk Report & Reliable Entry Point Trade Alerts - Newser
Has Lexaria Bioscience Corp. Equity Warrant formed a bullish divergenceTrade Entry Report & Fast Exit and Entry Strategy Plans - Newser
What Fibonacci levels say about Lexaria Bioscience Corp. reboundWeekly Market Report & AI Optimized Trade Strategies - Newser
Using data models to predict Lexaria Bioscience Corp. stock movementJuly 2025 Catalysts & Long-Term Capital Growth Strategies - Newser
Can Lexaria Bioscience Corp. be recession proof2025 Support & Resistance & Reliable Volume Spike Alerts - mustnews.co.kr
Why Lexaria Bioscience Corp. Equity Warrant stock attracts strong analyst attentionWeekly Loss Report & Verified Momentum Stock Ideas - Newser
How Lexaria Bioscience Corp. stock performs during market volatility2025 Market Outlook & Advanced Technical Signal Analysis - newsimpact.co.kr
How to read the order book for Lexaria Bioscience Corp.Weekly Investment Report & Verified Entry Point Signals - Newser
Heatmap analysis for Lexaria Bioscience Corp. and competitorsDay Trade & Daily Technical Stock Forecast Reports - Newser
Lexaria Bioscience's DehydraTECH Platform: A Disruptive Force in GLP-1 Oral Delivery - AInvest
Lexaria Bioscience Completes Last Patient, Last Visit in Phase 1b GLP-1 Study, Awaits Laboratory Analysis - AInvest
Lexaria Bioscience announces last patient, last visit in Phase 1b GLP-1 study - Yahoo Finance
What MACD and RSI say about Lexaria Bioscience Corp. Equity WarrantGlobal Markets & AI Enhanced Trading Alerts - Newser
Lexaria Bioscience Corp. Equity Warrant Stock Support and Resistance Levels You Should KnowJuly 2025 Outlook & Technical Pattern Alert System - Newser
Risk vs reward if holding onto Lexaria Bioscience Corp.Earnings Miss & Stock Portfolio Risk Management - Newser
What makes Lexaria Bioscience Corp. stock price move sharplyBull Run & Technical Pattern Based Signals - Newser
Lexaria Bioscience Corp. Added to High Probability Setup ListWeekly Gains Report & Reliable Entry Point Trade Alerts - sundaytimes.kr
Lexaria Bioscience's Contract Research Organization Completes Last Patent Last Visit Study Milestone In Lexaria's Phase 1b Glucagon-Like Peptide-1 Study In Australia, GLP-1-H24-4 - 富途牛牛
Lexaria completes patient dosing in GLP-1 study, final results expected Q4 - Investing.com Australia
Lexaria's GLP-1 Breakthrough: A Paradigm Shift in Oral Drug Delivery and Market Leadership Potential - AInvest
Experis Named Leader in Everest Group's 2025 U.S. IT Contingent Talent and Strategic Solutions PEAK Matrix Assessment - AInvest
Lexaria Bioscience stock rises after completion of GLP-1 study milestone By Investing.com - Investing.com South Africa
Lexaria Bioscience stock rises after completion of GLP-1 study milestone - Investing.com Australia
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone - TradingView
Lexaria's GLP-1 Drug Shows Better Tolerability Than Rybelsus in Latest Trial Phase - Stock Titan
Lexaria Bioscience Corp. At Critical Juncture — Bounce or BreakdownJuly 2025 Final Week & Risk Controlled Stock Pick Alerts - beatles.ru
What MACD and RSI say about Lexaria Bioscience Corp.Market Performance Recap & Growth Focused Stock Pick Reports - Newser
How Interest Rate Changes Impact Lexaria Bioscience Corp. Stock Performance2025 Price Action Summary & Free Technical Pattern Based Buy Signals - Newser
Market reaction to Lexaria Bioscience Corp.’s recent newsMarket Sentiment Review & Weekly Return Optimization Plans - Newser
Lexaria Bioscience Corp. Equity Warrant stock volume spike explainedJuly 2025 News Drivers & Fast Entry Momentum Alerts - Newser
How Lexaria Bioscience Corp. Equity Warrant stock performs during market volatility2025 Trading Volume Trends & AI Driven Stock Price Forecasts - Newser
What technical models suggest about Lexaria Bioscience Corp. Equity Warrant’s comebackPortfolio Growth Summary & Stock Timing and Entry Methods - Newser
Detecting support and resistance levels for Lexaria Bioscience Corp. Equity WarrantJuly 2025 Short Interest & AI Optimized Trading Strategy Guides - Newser
Will a bounce in Lexaria Bioscience Corp. offer an exitGap Down & Entry and Exit Point Strategies - Newser
Lexaria Bioscience Corp. Equity Warrant recovery potential after sell offJuly 2025 Summary & Precise Trade Entry Recommendations - Newser
Leading vs lagging indicators on Lexaria Bioscience Corp. Equity Warrant performanceLayoff News & Smart Investment Allocation Insights - Newser
Why Lexaria Bioscience Corp. stock attracts strong analyst attentionEarnings Trend Report & Long Hold Capital Preservation Plans - Newser
Will Lexaria Bioscience Corp. Equity Warrant stock go up soonPortfolio Update Summary & Community Consensus Trade Alerts - Newser
Should I hold or sell Lexaria Bioscience Corp. Equity Warrant nowFree Portfolio Health Check - newsyoung.net
Lexaria Bioscience Corp. Equity Warrant stock chart pattern explainedStrategy Playbook for Risk Controlled Trades - Newser
Lexaria Bioscience Corp Azioni (LEXX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):